Cms formulary id: «cms_formulary

Cms formulary id: «cms_formulary_id»

Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
DILANTIN 50 MG ORAL

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS
Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
DUETACT 30 MG-2 MG ORAL

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS
Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
DUETACT 30 MG-4 MG ORAL

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS
Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
GRIS-PEG 250 MG ORAL

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS
Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
PROTONIX IV 40 MG INTRAVEN.

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS
Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
TRICOR 145MG ORAL

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS
Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
TRICOR 48 MG ORAL

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS
Alliance CompleteCare
Future Formulary Change File
CMS FORMULARY ID: 13348
EFFECTIVE DATE: 6/1/2013

DRUG NAME
ZERIT 1 MG/ML ORAL

CHANGE DESCRIPTION
BRAND DELETION, ADD FRF GENERIC

REASON DESCRIPTION
REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW
GENERIC EQUIVALENT.

OTHER POSSIBLE DRUGS

Source: https://www.alamedaalliance.org/~/media/files/modules/publications/pharmacy/2013%20acc%20pharmacy%20documents/future%20formulary%20change_june%202013.pdf

luzart.ch

Stellungnahme Novartis gegenüber der Redaktion «ECO», per E-Mail am 23.01.2014 1. Die Anzahl und Höhe der Bussgelder gegen Pharmaunternehmen sind in den USA stark angestiegen. Auch Novartis ist davon betroffen. Ist das für Sie ein Anlass, Ihr Geschäftsgebaren zu ändern? Wenn ja / nein, warum / nicht? Die Novartis Pharmaceuticals Corporation (NPC) hat im Zusammenhang mit der Ankla

Microsoft word - gores.therakos.closingpressrelease.final

FOR IMMEDIATE RELEASE THE GORES GROUP COMPLETES THE ACQUISITION OF THERAKOS, INC. FROM ORTHO-CLINICAL DIAGNOSTICS, INC. LOS ANGELES, JANUARY 2, 2013 – The Gores Group, a global investment firm focused on acquiring controlling interests in mature and growing businesses, today announced that it has completed the acquisition of Therakos, Inc. from Ortho-Clinical Diagnostics, Inc